Cutting Edge: Proangiogenic Properties of Alternatively Activated Dendritic Cells

• Published in: The Journal of immunology (1950) Vol. 175; no. 5; pp. 2788 - 2792
• Main Authors: Riboldi, Elena, Musso, Tiziana, Moroni, Emanuela, Urbinati, Chiara, Bernasconi, Sergio, Rusnati, Marco, Adorini, Luciano, Presta, Marco, Sozzani, Silvano
• Format: Journal Article
• Language: English
• Published: United States Am Assoc Immnol 01-09-2005
• Subjects: Calcitriol - pharmacology; Dendritic Cells - physiology; Humans; Interleukin-10 - pharmacology; Neovascularization, Physiologic; RNA, Messenger - analysis; Vascular Endothelial Growth Factor A - genetics; Vascular Endothelial Growth Factor Receptor-2 - physiology
• ISSN: 0022-1767; 1550-6606
• DOI: 10.4049/jimmunol.175.5.2788

Angiogenesis plays an important role in tissue remodeling and repair during the late phase of inflammation. In the present study, we show that human dendritic cells (DC) that matured in the presence of anti-inflammatory molecules such as calcitriol, PGE2, or IL-10 (alternatively activated DC) selectively secrete the potent angiogenic cytokine vascular endothelial growth factor (VEGF) isoforms VEGF165 and VEGF121. No VEGF production was observed in immature or classically activated DC. Also, the capacity to produce VEGF was restricted to the myeloid DC subset. When implanted in the chick embryo chorioallantoic membrane, alternatively activated DC elicit a marked angiogenic response, which is inhibited by neutralizing anti-VEGF Abs and by the VEGFR-2 inhibitor SU5416. Therefore, alternatively activated DC may contribute to the resolution of the inflammatory reaction by promoting VEGF-induced angiogenesis.